Supernus Pharm
(SUPN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 181,381 | 192,248 | 100,304 | 66,398 | 33,498 |
| Marketable Securities | 165,692 | 163,770 | 39,736 | 23,723 | 28,692 |
| Receivables | 87,332 | 102,922 | 65,586 | 41,527 | 25,908 |
| Inventories | 26,628 | 25,659 | 16,304 | 16,801 | 12,587 |
| TOTAL | $472,644 | $493,487 | $228,451 | $151,404 | $105,946 |
| Non-Current Assets | |||||
| PPE Net | 17,068 | 4,095 | 5,124 | 4,344 | 3,874 |
| Investments And Advances | 591,773 | 418,798 | 133,638 | 75,410 | 55,009 |
| Intangibles | 24,840 | 31,368 | 36,019 | 36,350 | 976 |
| Other Non-Current Assets | 53,957 | 30,063 | 21,232 | 42,060 | 22,821 |
| TOTAL | $687,638 | $484,324 | $196,013 | $158,164 | $82,680 |
| Total Assets | $1,160,282 | $977,811 | $424,464 | $309,568 | $188,626 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 49,714 | 3,195 | 6,844 | 8,055 | 4,314 |
| Accrued Expenses | 107,629 | 155,975 | 111,586 | 69,377 | 51,947 |
| Other current liabilities | 3,244 | 2,183 | 4,283 | 3,101 | 497 |
| TOTAL | $160,587 | $161,353 | $123,000 | $80,742 | $56,934 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 287 | 209 | 176 |
| Other Non-Current Liabilities | 404,267 | 363,435 | 32,835 | 35,570 | 42,295 |
| TOTAL | $404,267 | $363,435 | $33,984 | $37,071 | $43,685 |
| Total Liabilities | $564,854 | $524,788 | $156,984 | $117,813 | $100,619 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 52,534 | 52,320 | 51,537 | 50,163 | 49,400 |
| Common Shares | 53 | 52 | 51 | 50 | 49 |
| Retained earnings | 199,548 | 86,492 | -26,823 | -84,288 | -175,509 |
| Other shareholders' equity | 7,417 | -3,158 | -747 | -134 | -488 |
| TOTAL | $595,428 | $453,023 | $267,480 | $191,755 | $88,007 |
| Total Liabilities And Equity | $1,160,282 | $977,811 | $424,464 | $309,568 | $188,626 |